Could a new drug combo reduce steroid use in chemo patients?
NCT ID NCT07662200
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a combination of anti-nausea drugs (netupitant/palonosetron) can effectively prevent nausea and vomiting in people with germ cell cancer receiving multi-day cisplatin chemotherapy, while using fewer steroids than usual. Ten participants will be randomly assigned to either the experimental steroid-sparing regimen or a standard regimen. The main goal is to see if this approach is feasible for a larger future study.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Netupitant/Palonosetron
- What this could lead to
- If successful, this could offer a way to manage chemotherapy-induced nausea and vomiting with fewer steroids, potentially reducing steroid-related side effects.
- What could go wrong
- This is a very early pilot study with only 10 participants, so results may not apply broadly. The experimental regimen may not control nausea as well as standard care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GERM CELL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ottawa Hospital Cancer Centre
Ottawa, Ontario, K1H 8L6, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.